Клиническая онкогематология

Клиническая онкогематология

Фундаментальные исследования и клиническая практика

Menu

  • Home
  • About
    • Aims and Scope
    • Editorial board
    • Indexing and Abstracting
    • Peer Review
    • Publishing Ethics and Malpractice Statement
    • Open Access Policy and Publication Fee
  • Archive
    • 2023
      • № 1/2023
    • 2022
      • № 1/2022
      • № 2/2022
      • № 3/2022
      • № 4/2022
    • 2021
      • № 1/2021
      • № 2/2021
      • № 3/2021
      • № 4/2021
    • 2020
      • Issue 1/2020
      • Issue 2/2020
      • Issue 3/2020
      • Issue 4/2020
    • 2019
      • №1/2019
      • № 2/2019
      • № 3/2019
      • № 4/2019
    • 2018
      • №1/2018
      • №2/2018
      • №3/2018
      • №4/2018
    • 2017
      • №1/2017
      • №2/2017
      • №3/2017
      • №4/2017
    • 2016
      • №1/2016
      • №2/2016
      • №3/2016
      • №4/2016
    • 2015
      • №1/2015
      • №2/2015
      • №3/2015
      • №4/2015
    • 2014
      • № 1/2014
      • №2/2014
      • №3/2014
      • №4/2014
    • 2013
      • №1/2013
      • №2/2013
      • №3/2013
      • №4/2013
  • Submission
    • Submit manuscript

Multiple Myeloma

AUTOIMMUNE THROMBOCYTOPENIA

SV Semochkin

NI Pirogov Russian National Research Medical University, 1 Ostrovityanova str., Moscow, Russian Federation, 117997; Municipal Clinical Hospital No. 52, 3 Pekhotnaya str., Moscow, Russian Federation, 123182

For correspondence: Prof. Sergei Vyacheslavovich Semochkin, MD, PhD, 3 Pekhotnaya str., Moscow, Russian Federation, 123182; Tel./fax: +7(495)369-00-36; e-mail: semochkin_sv@rsmu.ru

The interview was conducted by Prof. E.A. Osmanov, MD, PhD.

Read in PDF

  • ← Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma
  • Granulocyte-Macrophage Colony-Stimulating Factor and CAR-T Technology for Solid Tumors in Experiment →

Languages

  • ru 
  • en 
  • Supportive Therapy in Multiple Myeloma: Practical Recommendations
  • Primary Immune Thrombocytopenia and Thrombopoietin Receptor Agonists: Feasibilities of Treatment Discontinuation upon Achieving Stable Complete Platelet Response
  • Cardiovascular Complications of the Immunotherapy of Hematological Malignancies: A Literature Review
  • An Optimal Multi-Locus HLA-Typing in Potential Donors of Allogeneic Hematopoietic Stem Cells
  • BAALC-Expressing Leukemia Hematopoietic Stem Cells and Their Place in the Study of CBF-Positive Acute Myeloid Leukemias in Children and Adults